Rituximab plus Peg-interferon-α/ribavirin compared with Peg-interferon-α/ribavirin in hepatitis C–related mixed cryoglobulinemia
| العنوان: | Rituximab plus Peg-interferon-α/ribavirin compared with Peg-interferon-α/ribavirin in hepatitis C–related mixed cryoglobulinemia |
|---|---|
| المؤلفون: | Yoland Schoindre, Damien Sène, Laurent Perard, Benjamin Terrier, Brigitte Coppéré, Alexandre Karras, Patrice Cacoub, Lucile Musset, Jean-Charles Piette, François Blanc, Mathieu Resche Rigon, M. Rosenzwajg, David Saadoun |
| المصدر: | Blood. 116:326-334 |
| بيانات النشر: | American Society of Hematology, 2010. |
| سنة النشر: | 2010 |
| مصطلحات موضوعية: | Male, medicine.disease_cause, Biochemistry, Gastroenterology, Polyethylene Glycols, Cohort Studies, Antibodies, Monoclonal, Murine-Derived, chemistry.chemical_compound, Prospective Studies, education.field_of_study, Remission Induction, Antibodies, Monoclonal, virus diseases, Hematology, Hepatitis C, Middle Aged, Cryoglobulinemia, Recombinant Proteins, Treatment Outcome, RNA, Viral, Drug Therapy, Combination, Female, Rituximab, medicine.drug, medicine.medical_specialty, Hepatitis C virus, Immunology, Population, Alpha interferon, Interferon alpha-2, Antiviral Agents, Internal medicine, Ribavirin, medicine, Humans, education, Interferon alfa, Aged, business.industry, Interferon-alpha, Cell Biology, Hepatitis C, Chronic, medicine.disease, digestive system diseases, chemistry, business |
| الوصف: | Treatment of hepatitis C (HCV)–mixed cryoglobulinemia (MC) may target either the viral trigger (HCV) or the downstream B-cell clonal expansion. Prospective cohort study of 38 HCV-MC patients who received a combination of rituximab (375 mg/m2) once a week for 1 month followed by Peg-interferon-α (Peg-IFN-α; 2a, 180 μg or 2b, 1.5 μg/kg) weekly plus ribavirin (600-1200 mg) daily for 48 weeks were compared with 55 HCV-MC patients treated by Peg-IFN-α/ribavirin with the same modalities. In the whole population of HCV-MC patients (n = 93), a complete clinical response was achieved in 73.1% (68 of 93), cryoglobulin clearance in 52.7% (49 of 93), and a sustained virologic response in 59.1% (55 of 93). Compared with Peg-IFN-α/ribavirin, rituximab plus Peg-IFN-α/ribavirin–treated patients had a shorter time to clinical remission (5.4 ± 4 vs 8.4 ± 4.7 months, P = .004), better renal response rates (80.9% vs 40% of complete response, P = .040), and higher rates of cryoglobulin clearance (68.4% vs 43.6%, P = .001) and clonal VH1-69+ B-cell suppression (P < .01). Treatment was well tolerated with 11% of discontinuation resulting from antiviral therapy and no worsening of HCV RNA under rituximab. Our findings indicate that rituximab combined with Peg-IFN-α/ribavirin is well tolerated and more effective than Peg-IFN-α/ribavirin in HCV-MC. |
| تدمد: | 1528-0020 0006-4971 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd14dc4d2f7600b5ba3a1b0e39536dce https://doi.org/10.1182/blood-2009-10-248518 |
| رقم الأكسشن: | edsair.doi.dedup.....fd14dc4d2f7600b5ba3a1b0e39536dce |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15280020 00064971 |
|---|